Sai Life Sciences Limited is an innovator-focused, contract research, development, and manufacturing organization (DRDMO). They provide end to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities, to global pharmaceutical innovator companies and biotechnology firms. It is the fastest-growing Indian CRDMOs among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR from FY ‘22 to FY ’24. CRDMO platform provides multiple entry points for them to acquire customers in the intermediate stages of their new drug discovery to commercialization journey.
Strengths And Risks
+ One of the largest integrated Indian CRDMOs: Sai Life Sciences is one of the largest integrated CRDMOs among listed Indian peers in terms of revenue from operations for the FY '24, serving as a one-stop platform for discovery, development and manufacturing.
+ CDMO platform with a diverse mix of commercial and under-development molecules : Company provides end-to-end development and manufacturing services covering the full value chain for intermediates and APIs. As of March 2024, its development and manufacturing portfolio constituted 38 products used in the production of 28 commercial drugs, including seven blockbusters.
+ Fast-growing, integrated Discovery capabilities: Company's Discovery business grew at a CAGR of 34.77% from FY '22 to FY '24. They added 230 new customers from the FY '19 to the FY '24, and served more than 200 customers in each of the Financial Years 2022, 2023 and 2024.
+ Long-standing diverse relationships: Company has a diversified customer base that helps to reduce customer concentration. As of March 31, 2024, no single customer accounted for more than 9% of its revenue from operations.
+ Modern R&D infrastructure: COmpany has established a fully integrated CRDMO platform with access to talent from across the world. They are the only CRDMO among the listed Indian peers that can conduct development activities in close proximity to their customers, and transfer technology for manufacturing back to India.
- Industry Risk: Company's financial performance depends on its ability to secure business from biotechnology and pharmaceutical customers and may be subject to risks, uncertainties and trends that affect its customers in these industries over which they have no control.
- Failure to develop or manufacture commercially viable drugs: They generate revenue from services related to small molecules throughout the drug discovery lifecycle, with R&D forming a crucial part of business.
- Extensive government regulation: Company operates in a highly regulated industry and various aspects of its operations are subject to extensive laws and regulations, in India and internationally, governing the pharmaceutical market. Any failure to obtain or renew statutory and regulatory licenses and approvals required to operate business, can impact the operations.
FAQs What is the Sai Life Sciences Limited IPO? +
When will the IPO open? +
What is the lot size of the IPO? +
How to apply for an IPO? +
When will the IPO be allotted? +
When is the IPO listing date? +
